Menu
Search
|

Menu

Close
X

EyePoint Pharmaceuticals Inc EYPT.OQ (NASDAQ Stock Exchange Global Market)

2.32 USD
-0.00 (-0.00%)
As of Dec 13
chart
Previous Close 2.32
Open 2.33
Volume 34,294
3m Avg Volume 101,417
Today’s High 2.33
Today’s Low 2.17
52 Week High 3.94
52 Week Low 0.93
Shares Outstanding (mil) 39.32
Market Capitalization (mil) 48.36
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
3
FY17
8
FY16
2
FY15
27
EPS (USD)
FY19
-0.441
FY18
-1.056
FY17
-0.519
FY16
-0.681
FY15
0.185
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.39
Price to Sales (TTM)
vs sector
6.41
6.22
Price to Book (MRQ)
vs sector
3.63
5.20
Price to Cash Flow (TTM)
vs sector
--
24.17
Total Debt to Equity (MRQ)
vs sector
0.00
16.03
LT Debt to Equity (MRQ)
vs sector
0.00
11.49
Return on Investment (TTM)
vs sector
-92.63
14.96
Return on Equity (TTM)
vs sector
-108.05
16.52

EXECUTIVE LEADERSHIP

Goran Ando
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Nancy Lurker
President, Chief Executive Officer, Independent Director, Since 2016
Salary: --
Bonus: --
David Price
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Ron Honig
Senior Vice President, General Counsel, Secretary, Since 2018
Salary: --
Bonus: --
Leonard Ross
Vice President - Finance, Since 2018
Salary: $255,234.00
Bonus: $77,091.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

480 Pleasant St Ste B300
WATERTOWN   MA   02472-2468

Phone: +1617.9265000

Eyepoint Pharmaceuticals, Inc., formerly pSivida Corp, develops drug delivery products primarily for the treatment of chronic eye diseases. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.

SPONSORED STORIES